Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global thrombin market size was valued at USD 665 million in 2023, driven by the increasing prevalence of blood disorders such as hemophilia across the globe. The market is expected to grow at a CAGR of 5.50% during the forecast period of 2024-2032, with the values likely to rise from USD 701.3 million in 2024 to USD 1075.9 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Thrombin, also known as coagulation factor II, is a serine protease that regulates hemostasis and maintains blood coagulation. It is naturally produced in humans and is involved in the coagulation cascade. There are three thrombin products: bovine thrombin, human thrombin, and recombinant thrombin. All of them are approved by the Food and Drug Administration (FDA) for topical application as a solution, in combination with fibrinogen as a glue, or sprayed into a mist. As a hemostatic agent, thrombin can minimize blood loss during surgical procedures.
The thrombin market demand is driven by the rising incidence of hemophilia, an inherited bleeding disorder. It is estimated that 1 in every 6000-10,000 males have this bleeding disorder. Approximately 30,000 – 33,000 males are living with hemophilia in the United States, with the highest prevalence found in the Midwestern and Northeastern states. Another key driver is the extensive application of thrombin in the healthcare sector, owing to the growing prevalence of trauma cases. Moreover, the advancement in the healthcare infrastructure as well as the rising disposable income of the population is projected to contribute to the market growth in the forecast period.
Intensive Research to Expedite Thrombin Market Growth
Thrombin is extensively used in the hemostatic field. It can provide a direct clotting effect on the exposed blood, controlling minor oozing and bleeding during surgery. Intensive research activities by academic institutes and pharmaceutical companies revealed several therapeutic applications of thrombin including burn treatment, wound management, and tumor vasculature blockade therapy.
In November 2023, a study published in Nature, compared active (gelatin-thrombin-based product Floseal) and passive (modified absorbable polymers powder PerClot) hemostatic agents to find their effectiveness in controlling hepatic bleeding. It was observed that Floseal (active hemostatic group) was faster to achieve homeostasis than PerClot (passive hemostatic group) which was attributed to the presence of thrombin component in it. The continuous research and development efforts to find novel therapeutics and improve existing uses of thrombin are anticipated to contribute to the thrombin market share.
Growing Applications of Recombinant Thrombin
The regulatory health body FDA has approved many thrombin-based products including recombinant thrombin. Several drugs containing recombinant thrombin are currently undergoing clinical trials for their therapeutic homeostatic effect. In April 2023 , Baxter International Inc., announced the launch of Floseal + Recothrom, a novel flowable hemostat with a recombinant thrombin. The new addition to its surgical portfolio was revealed at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023. Faster to prepare than FLOSEAL with human thrombin, the homeostat is manufactured using recombinant DNA technology.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Product
Market Breakup by Dosage Form
Market Breakup by End User
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America is experiencing significant growth in the demand for thrombin due to the increasing prevalence of blood disorders and trauma cases which requires the need for effective hemostatic agents. In addition, the robust support from government and non-government organizations is further accelerating market growth.
In August 2023 , Oklahoma Medical Research Foundation scientist Ray Rezaie received a USD 1.7 million grant from the National Institutes of Health (NIH) to support his work on blood clotting and the interaction of associated three molecules including thrombin. The funding will accelerate the research on mechanisms controlling clotting and inflammation, leading to promising medications for stroke, heart attack, and sepsis.
Europe also holds a considerable thrombin market share owing to the presence of well-established healthcare infrastructure. The existence of leading pharmaceutical companies is fuelling research and development (R&D) activities of thrombin, which is expanding the market size. In Asia Pacific, the growing population size, rising healthcare expenditure, and the increasing impetus for improved patient care are driving the market growth. The region is anticipated to offer lucrative growth opportunities for the key market players due to the surge in the adoption of thrombin-based hemostats in healthcare facilities.
In October 2023 , Aronora, a clinical-stage biotech based in the United States, secured investment from an early-stage life sciences investment fund NYBC Ventures. The funds will be used to develop the lead drug candidates E-WE thrombin (AB002) and Gruticibart (AB023) and expand its manufacturing capacities. E-WE thrombin, an anticoagulant, has demonstrated positive results in phase 2a clinical trials. The increased investment in research and development by pharmaceutical companies and research organizations will improve the safety and efficacy of thrombin-based products, elevating thrombin market value in the forecast period.
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product |
|
Breakup by Dosage Form |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us today for customized, data-driven solutions tailored to your unique requirements!
The market attained a value of about USD 665 million in 2023, driven by the increasing prevalence of blood disorders such as hemophilia across the globe.
The market is anticipated to grow at a CAGR of 5.50% during the forecast period of 2024-2032, likely to reach a market value of USD 1075.9 million by 2032.
The increased expenditure on healthcare and the rising patient awareness are some of the factors contributing to the increasing market demand.
The growing application of thrombin-based products, including recombinant thrombin in the healthcare sector, is the major trend in the market. In April 2023, Baxter International Inc. announced the launch of Floseal + Recothrom, a novel flowable hemostat with a recombinant thrombin. Faster to prepare than FLOSEAL with human thrombin, the homeostat is manufactured using recombinant DNA technology.
The various products in the market are bovine, human, and recombinant thrombin.
Based on the dosage form, the market is segmented into powder form and solution form.
Major end users of thrombin include hospitals, diagnostic centers and clinics, academics, and research institutes, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Pfizer Inc., Johnson and Johnson, Baxter International, Inc., Shanghai RAAS Blood Products Co., Ltd., Japan Blood Products Organization, Mochida Pharmaceutical Co., Ltd, Haematologic Technologies Inc., GE Healthcare, Hualan Biological, AMRESCO Inc, CSL Behring, Mallinckrodt Pharmaceuticals, BIOFAC A/S, Biomed-Lublin S.A., and Hualan Biological Engineering, Inc.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124